DoH Policies screened during the period: 1 January 2023 - 31 March 2023
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- Anti Fraud Policy Statement (PDF 516KB)
- Provision of Support Services for Adults with Acquired Brain Injury (ABI) and their Carers Service Specification (PDF 285KB)
- Review of General Surgery (PDF 949KB)
- NICE Public Health Guideline NG209 - Tobacco: preventing uptake, promoting quitting and treating dependence (updates and replaces NG92) (PDF 528KB)
- NICE Technology Appraisal TA874 - Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (PDF 518KB)
- NICE Technology Appraisal TA873 - Cannabidiol for treating seizures caused by tuberous sclerosis complex (PDF 515KB)
- NICE Technology Appraisal TA871 - Eptinezumab for preventing migraine (PDF 516KB)
- NICE Technology Appraisal TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (review of TA505) (PDF 515KB)
- NICE Technology Appraisal TA868 - Vutrisiran for treating hereditary transthyretin-related amyloidosis (PDF 513KB)
- NICE Technology Appraisal TA866 - Regorafenib for previously treated metastatic colorectal cancer (PDF 624KB)
- NICE Technology Appraisal TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (PDF 516KB)
- NICE Technology Appraisal TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (partial review of TA379) (PDF 516KB)
- NICE Technology Appraisal TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over. (PDF 515KB)
- NICE Technology Appraisal TA862 - Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (PDF 626KB)
- NICE Technology Appraisal TA861 - Upadacitinib for treating active non-radiographic axial spondyloarthritis (PDF 516KB)
- NICE Clinical Guideline NG230 - Thyroid cancer: assessment and management (PDF 515KB)
- NICE Technology Appraisal TA860 - Maribavir for treating refractory cytomegalovirus infection after transplant (PDF 517KB)
- NICE Clinical Guideline NG229 - Fetal monitoring in labour (partially replaces CG190) (PDF 520KB)
- NICE Technology Appraisal TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (PDF 858KB)
- NICE Clinical Guideline NG228 - Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management (PDF 517KB)
- NICE Technology Appraisal TA856 - Upadacitinib for treating moderately to severely active ulcerative colitis (PDF 517KB)
- NICE Technology Appraisal TA855 - Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (PDF 516KB)
- NICE Clinical Guideline NG225 - Self-harm: assessment, management and preventing recurrence (updates and replaces CGs 16 & 133) (PDF 531KB)
- NICE Technology Appraisal TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia (PDF 514KB)
- NICE Technology Appraisal TA854 - Esketamine nasal spray for treatment-resistant depression (PDF 515KB)
- NICE Technology Appraisal TA852 - Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (review of TA669) (PDF 515KB)
- NICE Technology Appraisal TA851 - Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (PDF 516KB)
- NICE Clinical Guideline NG226 - Osteoarthritis in over 16s: diagnosis and management (updates and replaces CG177) (PDF 517KB)
- NICE Technology Appraisal TA850 - Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (PDF 516KB)
- NICE Technology Appraisal TA849 - Cabozantinib for previously treated advanced hepatocellular carcinoma (PDF 517KB)